



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/069,180	02/15/2002	Shigenori Ohkawa	2628 USOP	1643

7590

08/07/2003

Mark Chao
Takeda Pharmaceuticals North America Inc
Suite 500
475 Half Day Road
Lincolnshire, IL 60069

EXAMINER

MCKENZIE, THOMAS C

ART UNIT

PAPER NUMBER

1624

DATE MAILED: 08/07/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/069,180

Applicant(s)

OHKAWA ET AL.

Examiner

Thomas McKenzie, Ph.D.

Art Unit

1624

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 15 February 2003.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-19 and 25-28 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-12, 17-19 and 25-28 is/are rejected.
- 7) ☒ Claim(s) 13-16 is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) <u>5</u> | 6) <input type="checkbox"/> Other: |

DETAILED ACTION

1. This action is in response to an application filed on 2/15/02. There are twenty-three claims pending and twenty-three under consideration. Claims 1-17 are compound claims. Claim 19 is a composition claim. Claims 25-28 are use claims. Claim 19 is a method of synthesis claim. This is the first action on the merits. The application concerns some furo[2,3-f]indole compounds, compositions, and uses thereof.

Claim Rejections - 35 USC § 112

2. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-6, 9-12, 17-19, and 25-28 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Throughout these claims Applicants refer to "further substituted" rings, "optionally substituted cyclic amino groups, optionally substituted phenyl group", and "optionally substituted hydrocarbon group". Substituted by what?

3. Claims 1-12, 17-19, and 25-28 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. In the last line of claim 1, Applicants have "R is *** an acyl group". The term acyl is indefinite.

Does this embrace the acids of sulfur and phosphorus? How is the acyl group attached? Is it through the central atom of the acid group or through some other carbon atom? What is the specific stem, i.e. if acyl is $RC(O)$, what is R? In acyl groups derived from carboxylic acids, does the carbon count include the carbonyl carbon atom?

4. Claims 10-12 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The phrase "cyclic amino group is indefinite. Paragraph 5, page 31 gives a definition of this using open language. What else is included in the term? An amino group is $-NH_2$ and is not normally cyclic. Where applicant acts as his or her own lexicographer to specifically define a term of a claim contrary to its ordinary meaning, the written description must clearly redefine the claim term and set forth the uncommon definition so as to put one reasonably skilled in the art on notice that the applicant intended to so redefine that claim term. *Process Control Corp. v. HydReclaim Corp.*, 190 F.3d 1350, 1357, 52 USPQ2d 1029, 1033 (Fed. Cir. 1999). The term is indefinite because the specification does not clearly redefine the term.

5. Claims 17, 19, and 25-28 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly

claim the subject matter which applicant regards as the invention. The word “prodrug” in each of these claims is indefinite. What are the structures of these prodrugs? The issue on second paragraph is whether the structures of the claimed compounds are clearly defined. Applicants' “prodrugs” are molecules whose structure lie outside the subject matter of the formula of claim 1, but upon metabolism in the body are converted to active compounds falling within the structural scope of formula 1. The claim describes the function intended but provides no specific structural guidance to what constitutes a “prodrug”.

6. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 17, 19, and 25-28 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for salts of claimed compounds, does not reasonably provide enablement for prodrugs generally. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims. “The factors to be considered [in making an enablement rejection] have been summarized as the quantity of experimentation necessary, the amount of direction or guidance presented, the presence or absence of working examples, the

nature of the invention, the state of the prior art, the relative skill of those in that art, the predictability or unpredictability of the art and the breadth of the claims”, *In re Rainer*, 146 USPQ 218 (1965); *In re Colianni*, 195 USPQ 150, *Ex parte Formal*, 230 USPQ 546. a) Finding a prodrug is an empirical exercise. Predicting if a certain ester of a claimed alcohol, for example, is in fact a prodrug, that produces the active compound metabolically, in man, at a therapeutic concentration and at a useful rate is filled with experimental uncertainty. Although attempts have been made to predict drug metabolism *de novo*, this is still an experimental science. For a compound to be a prodrug, it must meet three tests. It must itself be biologically inactive. It must be metabolized to a second substance in a human at a rate and to an extent to produce that second substance at a physiologically meaningful concentration. Thirdly, that second substance must be biologically active. Determining whether a particular compound meets these three criteria in a clinical trial setting passes the threshold of undue experimentation. A large degree of experimentation is necessary. b) There is no direction in the specification to the determination of whether a compound is a prodrug nor is there any direction as to possible structures of such compounds. c) There is no working example of a prodrug of a compound formula (I). d) The nature of the invention is clinical use of compounds and the pharmacokinetics of substances in the human

body. e) The state of the prodrug art is summarized by Wolff (Medicinal Chemistry). The table on the left side of page 976 outlines the research program to be undertaken to find a prodrug. The second paragraph in section 10 and the paragraph spanning pages 976-977 indicate the low expectation of success. In that paragraph the difficulties of extrapolating between species are further developed. Since, the prodrug concept is a pharmacokinetic issue, the lack of any standard pharmacokinetic protocol discussed in the last sentence of this paragraph is particularly relevant. Banker (Modern Pharmaceutics) in the first sentence, third paragraph on page 596 states that "extensive development must be undertaken" to find a prodrug. f) Wolff (Medicinal Chemistry) in the last paragraph on page 975 describes the artisans making Applicants prodrugs as a collaborative team of synthetic pharmaceutical chemists and metabolism experts. g) The lack of predictability in finding prodrugs was discussed above. h) The breadth of the claims includes all of the hundreds of thousands of compounds of the formula given in claim 1 as well as the presently unknown list potential prodrug derivatives embraced by claim 17.

Thus, undue experimentation will be required to determine if any particular derivative is, in fact, a prodrug.

7. Claims 17, 19, and 25-28 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for making salts of claimed compounds, does not reasonably provide enablement for making prodrugs generally. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make the invention commensurate in scope with these claims. Nowhere in the specification are directions given for preparing the “prodrugs” of the claimed compounds. Since the structures of these “prodrugs” are uncertain, direction for their preparation must be even more unclear.

8. Claims 25-28 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for treating cranial trauma, does not reasonably provide enablement for treating the other claimed diseases. The specification does not enable any physician skilled in the art of medicine, to use the invention commensurate in scope with these claims. The factors to be considered in making an enablement rejection have been summarized above. a) Determining if any particular claimed compound would treat any particular cardiovascular, neurodegenerative, urinary, or restenosis disease would require synthesis of the compound, formulation into a suitable dosage form, and subjecting it clinical trials with a number of fundamentally different diseases described below, or to testing

them in an assay known to be correlated to clinical efficacy of such treatment.

This is a large degree of experimentation. b) There is a *single in vitro* assay described in the passage spanning line 22, page 188 to line 5, page 190 with data for two species but it is unclear if this assay is correlated to the claimed diseases.

c) There is no working example of treatment of any disease in man or animals. d)

The nature of the invention is clinical treatment of disease, which involves physiological activity. e) The state of the clinical arts in lipoperoxidase inhibitors

is discussed by Delanty (Arch. Neurol). The treatment of traumatic CNS injury

with an inhibitor of lipoperoxide production is found in the third complete paragraph, second column page 1268. The lack of clinical efficacy for stroke,

neurodegenerative diseases, AIDS, and epilepsy with such inhibitors is found in the passage spanning pages 1267 to 1269. With reference to claim 26, Applicants

should note the first sentence of the abstract of Solin (Kidney Int.), "little is known of their significance and respective scavenger systems in human glomerular

diseases". Both dysuria and urinary incontinence are glomerular diseases.

f) The artisan using Applicants invention would be a physician with a MD degree and several years of experience. g) It is well established that "the scope of

enablement varies inversely with the degree of unpredictability of the factors involved", and physiological activity is generally considered to be an unpredictable

factor. See *In re Fisher*, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970). h) The scope of the claims involves all of the thousands of compounds of claim 1 as well as the hundred of diseases embraced by the term neurodegenerative. Thus, the scope of claims is very broad.

MPEP §2164.01(a) states, "A conclusion of lack of enablement means that, based on the evidence regarding each of the above factors, the specification, at the time the application was filed, would not have taught one skilled in the art how to make and/or use the full scope of the claimed invention without undue experimentation. *In re Wright*, 999 F.2d 1557,1562, 27 USPQ2d 1510, 1513 (Fed. Cir. 1993)." That conclusion is clearly justified here and undue experimentation will be required to practice Applicants' invention.

9. Claims 25-28 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for treating cranial trauma, does not reasonably provide enablement for preventing any diseases. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims. Applicants are not enabled for preventing any of these diseases. The only established prophylactics are vaccines not the furo[2,3-f]indole compounds such as present here. In addition, it is presumed that "prevention" of the claimed diseases would require a method of identifying those individuals who will develop the

claimed diseases before they exhibit symptoms. There is no evidence of record that would guide the skilled clinician to identify those who have the potential of becoming afflicted.


The Examiner suggests deletion of the word "preventing".

Allowable Subject Matter

10. Claims 13-16 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Claims 1-12 and 18 would be allowable if rewritten or amended to overcome the rejection(s) under 35 U.S.C. 112, second paragraph, set forth in this Office action.

Conclusion

11. Please direct any inquiry concerning this communication or earlier communications from the Examiner to Thomas C McKenzie, Ph. D. whose telephone number is (703) 308-9806. The FAX number for before final amendments is (703) 872-9306. The Examiner is available from 8:30 to 5:30, Monday through Friday. If attempts to reach the Examiner by telephone are unsuccessful, you can reach the Examiner's supervisor, Mukund Shah at (703) 308-4716. Please direct general inquiries or any inquiry relating to the status of this application to the receptionist whose telephone number is (703) 308-1235.


Mukund Shah
Supervisory Patent Examiner
Art Unit 1624

TCMcK
August 6, 2003

